References
- 1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov; 3(11): e442. 2011-30.10.1371/journal.pmed.0030442166460117132052
- 2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrium fibrillation. N Engl J Med. 2009 Sep;361(12):1139-51. DOI: 10.1056/NEJMoa090556110.1056/NEJMoa090556119717844
- 3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrilation. N Engl J Med. 2011 Sep; 365(10):883-91. DOI: 10.1056/NEJMoa100963810.1056/NEJMoa100963821830957
- 4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep; 365(11):981-92. DOI: 10.1056/NEJMoa110703910.1056/NEJMoa110703921870978
- 5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov; 369(22):2093-104. DOI: 10.1056/ NEJMoa131090710.1056/NEJMoa131090724251359
- 6. Scridon A, Șerban RC. Laboratory monitoring - a turning point in the use of new oral anticoagulants. Ther Drug Monit. 2016 Feb; 38(1):12-21. DOI: 10.1097/ FTD.000000000000024710.1097/FTD.000000000000024726352868
- 7. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2013 Jan;11:756-60. DOI: 10.1111/jth.1214910.1111/jth.1214923347120
- 8. Kuhn J, Gripp T, Flieder T, Dittrich M, Hendig D, Busse J, et al. UPLC-MRM mass spectrometry method for measurement of the coagulation inhibitors dabigatran and rivaroxaban in human plasma and its comparison with functional assays. PLoS ONE. 2015 Dec; 10(12):e0145478. DOI: 10.1371/journal.pone.014547810.1371/journal.pone.0145478468954626699714
- 9. Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014 Nov;100:230-5. DOI: 10.1016/j.jpba.2014.08.01110.1016/j.jpba.2014.08.01125173108
- 10. Cheng YH, Chen WC, Chang SY. Rapid determination of rivaroxaban in human urine and serum using colloidal palladium surface-assisted laser desorption/ ionization mass spectrometry. Rapid Commun Mass Spectrom. 2015 Nov; 29(21):1977-83. DOI: 10.1002/ rcm.730810.1002/rcm.730826443396
- 11. Rohde G. Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep; 872(1-2):43-50. DOI: 10.1016/j. jchromb.2008.07.015
- 12. Schellings MW, Boonen K, Schmitz EM, Jonkers F, van den Heuvel DJ, Besselaar A, et al. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thromb Res. 2016 Mar; 139:128-34. DOI: 10.1016/j. thromres.2016.01.012
- 13. Srinivas Reddy G, Prasad Reddy SLN, Shiva Kumar Reddy L. Development and validation of Hplc-Ms/Ms Method for Rivaroxaban quantitation in human plasma using solid phase extraction procedure. Orient J Chem. 2016 Dec; 32(2):1145-54. DOI: 10.13005/ojc/32024010.13005/ojc/320240
- 14. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical Method Validation. 2013 Sep; available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf
- 15. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. 2011, Jul; available at http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf
- 16. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008 Jan; 47(1):47-59. DOI: 10.2165/00003088-200847010-0000510.2165/00003088-200847010-0000518076218
- 17. EINSTEIN-PE Investigators, Bűller HR, Prins MH, Lensin AW, Decousus H, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr; 366(14):1287-97. DOI: 10.1056/NEJMoa111357210.1056/NEJMoa111357222449293
- 18. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75. DOI: 10.1038/nrd318510.1038/nrd318521164526
- 19. Gnoth MJ, Buetehorn U, Muenster U, Schwartz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011 Jul;338(1):372-80. DOI: 10.1124/ jpet.111.18024010.1124/jpet.111.18024021515813
- 20. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007 Jun; 45(6):335-44. DOI: 10.5414/CPP4533510.5414/CPP4533517595891
- 21. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 2013 Jun; 11(1):8. DOI: 10.1186/1477-9560-11-8 10.1186/1477-9560-11-8371668523809888